HK2 and breast cancer: Increased therapy responses have recently been reported when HK2 was inhibited with 3-bromopyruvate in hepatocarcinoma [142] and breast cancer [143], with resveratrol or sinomenine in lung cancer [106], with lonidamine in cholangiocarcinoma [144], and with luteolin in gastric cancer [145].